Kuros Biosciences【0RHR】銘柄情報

Kuros Biosciences AG (0RHR) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

8.56

( - )

買値

8.56

売値

8.56

出来高

14,410

平均取引量 (3 か月)

CHF 194,522

財務取引量

0.00 日の範囲 0.00

8.56 52 週間の範囲 8.56

時価総額

337.767M

企業価値

920.707M

前日終値

8.56

始値

時刻

3659

21.78498

(O)

最終取引時間

VWAP

歳入

146.06M

純利益

2.55M

発行済株式数

39,458,787

浮動株比率 (%)

73.92%

機関投資家保有比率 (%)

17.00%

配当利回り

PER

396.66

株価売上高倍率 (PSR)

6.43

1 株当たり利益 (EPS)

0.06

ベータ

0.74

Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Gran... Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Granules, an advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland. 詳細を表示

セクター

Health Care

業界

ウェブサイト

kurosbio.com

本社

Schlieren, Switzerland

設立

2026

Kuros Biosciences AG is listed in the Health Care sector of the ロンドン証券取引所 with ticker 0RHR. The last closing price for Kuros Biosciences was CHF8.56. Over the last year, Kuros Biosciences shares have traded in a share price range of CHF 8.56 to CHF 8.56.

Kuros Biosciences currently has 39,458,787 shares in issue. The market capitalisation of Kuros Biosciences is CHF337.77 million. Kuros Biosciences has a price to earnings ratio (PE ratio) of 396.66.

Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich

Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich Kuros...

Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth

Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of...

Annual General Meeting of Kuros Biosciences approves all resolutions

Annual General Meeting of Kuros Biosciences approves all resolutions Annual General Meeting of Kuros Biosciences approves all resolutions...

Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026

Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 Ad hoc announcement pursuant to Article 53 of the...

Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025

Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025 Ad-hoc announcement pursuant to Article 53 of the...

Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences

Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences Kuros Biosciences to provide investor updateat Octavian and...

Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion

Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot...

Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference

Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference Kuros Biosciences to present at the Piper Sandler 37th Annual...

Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025

Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025 Ad hoc...

Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025

Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025 Kuros Biosciences debuts commercial launch of MagnetOs...

期間 †	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	DE
4	0	0	0	0	0	DE
12	0	0	0	0	0	DE
26	8.56	8.56	8.56	16816	8.56	DE
52	8.56	8.56	8.56	16317	8.56	DE
156	8.56	8.56	8.56	10379	8.56	DE
260	8.56	8.56	8.56	6050	8.56	DE

0RHR - Frequently Asked Questions (FAQ)

What is the current Kuros Biosciences AG share price?

The current share price of Kuros Biosciences AG is CHF 8.56

How many Kuros Biosciences AG shares are in issue?

Kuros Biosciences AG has 39,458,787 shares in issue

What is the market cap of Kuros Biosciences AG?

The market capitalisation of Kuros Biosciences AG is CHF 337.77M

What is the 1 year trading range for Kuros Biosciences AG share price?

Kuros Biosciences AG has traded in the range of CHF 8.56 to CHF 8.56 during the past year

What is the PE ratio of Kuros Biosciences AG?

The price to earnings ratio of Kuros Biosciences AG is 396.66

What is the cash to sales ratio of Kuros Biosciences AG?

The cash to sales ratio of Kuros Biosciences AG is 6.43

What is the registered address of Kuros Biosciences AG?

The registered address for Kuros Biosciences AG is Wagistrasse 25, Schlieren, Zurich, 8952

What is the Kuros Biosciences AG website address?

The website address for Kuros Biosciences AG is kurosbio.com

superman2026 2分前

I agree with this. They didn't issue the rejection or objection, but they did support and advised that they support the objection whoever ask for their advise. Objection didn't come from them it came from MHRA or CHM and they did support it.

NWBO

sagedono 6分前

I waited until tonight to watch the video. Now how the hell am I going to get any sleep tonight. That amped me up more than I expected. Going to need one of my special cookies so I can doze off.
I will never get used to AI voices though!

NLST

Golden Cross 12分前

$HIRU AMEEREX CORPORATION ENGAGES PCAOB-REGISTERED AUDITOR VM CPA FIRM TO AUDIT 2024 AND 2025 FINANCIAL STATEMENTS

ATLANTA, GA -07/07/2026- Ameerex Corporation, formerly HIRU Corporation, (OTC: HIRU) (the “Company”), today announced that it has engaged VM CPA Firm, a PCAOB-registere

HIRU

wadegarret 13分前

Valuemind

Let me first say that my intentions when giving a negative reaction to a stock are not meant with any malice. I just feel like if I really don't like a stock, and I think the stock won't perform very well, that I am helping by giving my view . Now having said that, he

MarkMonkey 15分前

You’re right 983,244 shares but close enough I call it 1m- I unfortunately dropped 240k shares last month out of a different account.

Been following for a long time, some good people related/connected here

SGMD

GlitteringWanderer70 16分前

Yes of course the hitters are also getting dinged up…and don’t forget the umpires behind home plate too…They get dinged up as well…it’s a long MLB season..every team plays 162 games…plus playoffs…I watch a lot of baseball games and you don’t see one go by without players fouling 90-100+ mph fastball

KBLB

georgejjl 19分前

Autophagy in Alzheimer's disease: mechanisms, clinical trials, and horizons

A new paper by Dr. Marwan Sabbagh MD, et. al. about blarcamesine

https://karger.com/ndd/article-pdf/doi/10.1159/000553506/4559230/000553506.pdf

Good luck and GOD bless

AVXL

mgland 30分前

Great news. Huge confirmation. The bug has been swatted

Truthsocial 32分前

India was a major player in the EFS FDA APPROVAL
While initial findings have been shared, the company intends to publish comprehensive results in a leading medical journal later in the year following full data finalization.
Future Trials: The trial is approved for 30 patients, with p

RDGL

Biotech_Tradez 34分前

Heard Electrome was not happy with Mayer on a number of different fronts.

They were not very keen on this deal with BIEL because it is a distraction from what they are doing with their own patent-pending device that was invented by the new CEO. He is taking it to DARPA for funding. On

BIEL

shajandr 42分前

SAM ALTMAN = LIZZY HOLMES with better hair.

ron_66271 44分前

The Discovery Document by QE Proves RICO.

Project West.

The BOD was reviewed on the status of the project three times from the discovery document.
Therefore the BOD past and present are compliant if current members have not voiced their concerns about settlement

RKT

Porch Honkey 48分前

When they are ready, there will be investors here that you have never seen before, gl.

GTCH

LOB 50分前

Blaqclouds Wyoming

@blaqclouds_WY
#Blaqclouds • #DEFI💎 http://BLAQpay.io http://AplloNFT.io🔎• #NFT #WEB3 Dev • DM 📩 for Collab
Social Media InfluencerPAblaqclouds.io
Joined May 2020
1,260 Following
123.5K Followers

BCDS

Juststoppingby 53分前

My AI responds to clarification on “EDGAR packages are being validated”.

When I say “EDGAR packages are being validated,” I’m talking about a very specific, very technical stage in the SEC-filing process — one that happens right before a delinquent filer begins submitting forms.

CRTG

zakattack 54分前

They put out a pr dec 2025 stating they would increase to 49% in gncp but no filings proving they actually did so sp again where is the proof pdiv paid anything or did anything for the land claims prove me wrong

GNCP

nowwhat2 57分前

xxxxxxxxxxxx wow

https://investorshub.advfn.com/uimage/uploads/2026/7/13/i[smibtc_july_12_2m_7pm_200_64_diag_point.jpg

https://investorshub.advfn.com/uimage/uploads/2026/7/13/wtzkebtc_july_12_2m_9pm_update_200_64_point_tl.jpg

BTCUSD

mikeo56 58分前

Smoking in Aussie land .
Up 30 %
Tomorrow in USA will be good.

DTREF

choo choo trader 1時間前

Thanks for reposting it Striper, somehow I missed it when gdog initially posted it. That is about the most informative video I have seen so far laying out the whole risk/reward story of $NLST.

NLST

ron_66271 1時間前

No The FDIC and JPM both Had a Claim Against $24 Billion.

Inflated claim of $27*2=$54.00 Billion against the Estate to make WMI as insolvent for the Senior Note holders when JPM controlled the BK process because invested in the Senior Notes of WMI with the takeover.

RKT

skitahoe 1時間前

Doc, I've been saying this for ages, but not that the full EDEN based facility must be completed. I believe the UK and other countries would simply like to know it's close. They'd like to know the EDEN is making commercial quality vaccine and that it can be delivered in quantity, and they'd like t

NWBO

FDA-agent-2 1時間前

nobody is getting paid here .no editiing or no research which cost money.

DBMM

Johnnycombat10 1時間前

I see both sides of the debate . The company has every right to state their position just as you have your right to speak yours. But you have right to demand anything from anyone on this board. You have no rights other than the right to speak our mind. And I have the to tell you to pound salt. If I

DBMM

AstroGuru64 1時間前

The issue still lies with the Treasury Department.

FNMA

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Kuros Biosciences AG (0RHR)

Kuros Biosciences AG (0RHR) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

主要統計と詳細

Kuros Biosciences AG について

0RHR 最新ニュース

Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich

Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth

Annual General Meeting of Kuros Biosciences approves all resolutions

Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026

Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025

Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences

Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion

Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference

Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025

Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025

Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich

Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth

Annual General Meeting of Kuros Biosciences approves all resolutions

Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026

Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025

Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences

Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion

Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference

0RHR - Frequently Asked Questions (FAQ)

0RHR 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

ADVFNに参加する理由

プロトレーダー向けの高機能ツール

広告を削除する